Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMEA says clarification on dedicated facilities forthcoming

This article was originally published in The Gold Sheet

Executive Summary

EMEA said a clarification on the status of the revision of Chapter 5 of its EU GMP guide concerning dedicated facilities will be available at the end of the year. Section 6 of Chapter 5 GMP Guide currently states that "in order to minimize the risk of a serious medical hazard due to cross-contamination, dedicated and self-contained facilities must be available for the production of particular medicinal products such as highly sensitizing materials (e.g. penicillins) or biological preparations (e.g. from live microorganisms)." It further noted that "the production of certain additional products such as certain antibiotics certain hormones, certain cytotoxics, certain highly active drugs and non-medicinal products should not be conducted in the same facilities. However, the guidance does not specify which drugs those are. EMEA notes that "at present the GMP/GDP Inspectors Working Group agrees that the guide should indeed identify those products in which the use of dedicated facilities is mandatory. It is acknowledged that the drafting group needs input from toxicological and pharmacological experts in order to develop this part of the guidance so that it is based on well grounded scientific principles and this expertise has now been made available." EMEA says that its Safety Working Party will be developing the guidance and that a consultation draft will be submitted to the European Commission at yearend

You may also be interested in...

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective

Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts